Clinical Trial Search

Primary: Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS — 75 mcg daily with BID dosing

Primary: Dose Limiting Toxicity (DLT) - Percentage of Participants With DLT Events — 0; 0 percentage of participants.

Primary: Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib — 17.3; 28.1; 18.5 nmol/L

Primary: Area Under the Concentration-time Curve From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of Plasma Gepotidacin for Part 1a — 16733; 17495; 18646…

Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684 — 871; 861 nanogram*hour/milliliter (ng*h/mL)

Primary: Number of Participants With One or More Adverse Events — 11; 7 Participants

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 2; 3; 2 Participants

Primary: Maximum Observed Concentration (Cmax) of Belimumab — 221.3532 Micrograms per milliliter

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 3; 3; 3 Participants

Primary: Cmax: Maximum Observed Plasma Concentration for Ixazomib — 37.57 ng/mL

Primary: The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event — 5; 5; 3; 3 Participants

Primary: Cumulative Urinary Glucose Excretion Over 0 to 24 Hours — 69.45; 70.43; 78.29; 80.54 Grams

Primary: Subjects Achieving Normal Sinus Rhythm (NSR) in Patients With Paroxysmal AF — 0; 2; 0; 0 Participants

Primary: Time to Peak (Tmax) — 0.042; 0.033; 0.025; 0.033 hours

Primary: Safety and Tolerability of AZD5634 Following Inhaled Administration of Single-ascending Doses (SAD) (Part A) and Following Administration of Single Inhaled and IV Doses…